Metastatic gastric cancer – focus on targeted therapies
Judith Meza-Junco, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, CanadaAbstract: Gastric cancer (GC) is currently the second leading cause of cancer death worldwide; unfortunately, most patients will present with locally advanced or metastatic disease. Despite re...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/099185f5e7a940028ffa23aae2ec4e4e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:099185f5e7a940028ffa23aae2ec4e4e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:099185f5e7a940028ffa23aae2ec4e4e2021-12-02T02:05:39ZMetastatic gastric cancer – focus on targeted therapies1177-54751177-5491https://doaj.org/article/099185f5e7a940028ffa23aae2ec4e4e2012-06-01T00:00:00Zhttp://www.dovepress.com/metastatic-gastric-cancer-ndash-focus-on-targeted-therapies-a10179https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Judith Meza-Junco, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, CanadaAbstract: Gastric cancer (GC) is currently the second leading cause of cancer death worldwide; unfortunately, most patients will present with locally advanced or metastatic disease. Despite recent progress in diagnosis, surgery, chemotherapy, and radiotherapy, prognosis remains poor. A better understanding of GC biology and signaling pathways is expected to improve GC therapy, and the integration of targeted therapies has recently become possible and appears to be promising. This article focuses on anti-Her-2 therapy, specifically trastuzumab, as well as other epidermal growth factor receptor antagonists such as cetuximab, panitumub, matuzumab, nimotzumab, gefitinib, and erlotinib. Additionally, drugs that target angiogenesis pathways are also under investigation, particulary bevacizumab, ramucirumab, sorafenib, sunitinib, and cediranib. Other targeted agents in preclinical or early clinical development include mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors, anti-insulin-like growth factor, anti-heat shock proteins, and small molecules targeting Hedgehog signaling.Keywords: gastric cancer, targeted therapy, antiangiogenesis drugs, anti-EGFR drugsMeza-Junco JSawyer MBDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 137-146 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Meza-Junco J Sawyer MB Metastatic gastric cancer – focus on targeted therapies |
| description |
Judith Meza-Junco, Michael B SawyerDepartment of Oncology, Cross Cancer Institute, Edmonton, Alberta, CanadaAbstract: Gastric cancer (GC) is currently the second leading cause of cancer death worldwide; unfortunately, most patients will present with locally advanced or metastatic disease. Despite recent progress in diagnosis, surgery, chemotherapy, and radiotherapy, prognosis remains poor. A better understanding of GC biology and signaling pathways is expected to improve GC therapy, and the integration of targeted therapies has recently become possible and appears to be promising. This article focuses on anti-Her-2 therapy, specifically trastuzumab, as well as other epidermal growth factor receptor antagonists such as cetuximab, panitumub, matuzumab, nimotzumab, gefitinib, and erlotinib. Additionally, drugs that target angiogenesis pathways are also under investigation, particulary bevacizumab, ramucirumab, sorafenib, sunitinib, and cediranib. Other targeted agents in preclinical or early clinical development include mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors, anti-insulin-like growth factor, anti-heat shock proteins, and small molecules targeting Hedgehog signaling.Keywords: gastric cancer, targeted therapy, antiangiogenesis drugs, anti-EGFR drugs |
| format |
article |
| author |
Meza-Junco J Sawyer MB |
| author_facet |
Meza-Junco J Sawyer MB |
| author_sort |
Meza-Junco J |
| title |
Metastatic gastric cancer – focus on targeted therapies |
| title_short |
Metastatic gastric cancer – focus on targeted therapies |
| title_full |
Metastatic gastric cancer – focus on targeted therapies |
| title_fullStr |
Metastatic gastric cancer – focus on targeted therapies |
| title_full_unstemmed |
Metastatic gastric cancer – focus on targeted therapies |
| title_sort |
metastatic gastric cancer – focus on targeted therapies |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/099185f5e7a940028ffa23aae2ec4e4e |
| work_keys_str_mv |
AT mezajuncoj metastaticgastriccancerampndashfocusontargetedtherapies AT sawyermb metastaticgastriccancerampndashfocusontargetedtherapies |
| _version_ |
1718402693080285184 |